The association of TNF-α-308G/A and-238G/A polymorphisms with type 2 diabetes mellitus: a meta-analysis

被引:7
作者
Guo, Xiaoliang [1 ,2 ]
Li, Chenxi [1 ,2 ]
Wu, Jiawei [1 ,2 ]
Mei, Qingbu [1 ,2 ]
Liu, Chang [1 ,2 ]
Sun, Wenjing [1 ,2 ]
Xu, Lidan [1 ,2 ]
Fu, Songbin [1 ,2 ]
机构
[1] Harbin Med Univ, Lab Med Genet, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China
[2] Harbin Med Univ, Minist Educ, Key Lab Preservat Human Genet Resources & Dis Con, Harbin, Heilongjiang, Peoples R China
关键词
NECROSIS-FACTOR-ALPHA; GENOME-WIDE ASSOCIATION; PROMOTER GENE POLYMORPHISM; CORONARY-ARTERY-DISEASE; TNF-ALPHA; INSULIN-RESISTANCE; CHINESE PATIENTS; RISK LOCI; SUSCEPTIBILITY; IL-6;
D O I
10.1042/BSR20191301
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor necrosis factor-alpha (TNF-alpha) is involved in insulin resistance and has long been a candidate gene implicated in type 2 diabetes mellitus (T2DM), however the association between TNF-alpha polymorphisms -308G/A and -238G/A and T2DM remains controversial. The present study sought to verify associations between these polymorphisms and T2DM susceptibility using ameta-analysis approach. A total of 49 case-control studies were selected up to October 2018. Statistical analyses were performed by STATA 15.0 software. The odds ratios (ORs) and 95% confidence intervals were calculated to estimate associations. Meta-analyses revealed significant associations between TNF-alpha -308G/A and T2DM in the allele model (P=0.000); the dominant model (P=0.000); the recessive model (P=0.001); the overdominant model (P=0.008) and the codominant model (P=0.000). Subgroup analyses also showed associations in the allele model (P=0.006); the dominant model (P=0.004) and the overdominant model (P=0.005) in the Caucasian and in the allele model (P=0.007); the dominant model (P=0.014); the recessive model (P=0.000) and the codominant model (P=0.000) in the Asian. There were no associations between TNF-alpha -238G/A and T2DM in the overall and subgroup populations. Meta-regression, sensitivity analysis and publication bias analysis confirmed that results and data were statistically robust. Our meta-analysis suggests that TNF-alpha -308G/A is a risk factor for T2DM in Caucasian and Asian populations. It also indicates that TNF-alpha -238G/A may not be a risk factor for T2DM. More comprehensive studies will be required to confirm these associations.
引用
收藏
页数:16
相关论文
共 78 条
  • [31] Tumour necrosis factor-alpha promoter gene polymorphism at-308 (genotype AA) in Chinese subjects with Type 2 diabetes
    Ko, GTC
    Lee, SC
    Pu, YB
    Ng, MCY
    So, WY
    Thomas, N
    Chan, WB
    Cockram, CS
    Chan, JCN
    [J]. DIABETIC MEDICINE, 2003, 20 (02) : 167 - 168
  • [32] Association of Interleukin-10 Polymorphisms with Cytokines in Type 2 Diabetic Nephropathy
    Kung, Wan-Ju
    Lin, Ching-Chiang
    Liu, Shyh-Hwa
    Chaung, Hso-Chi
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2010, 12 (10) : 809 - 813
  • [33] Genomics of Islet (Dys)function and Type 2 Diabetes
    Lawlor, Nathan
    Khetan, Shubham
    Ucar, Duygu
    Stitzel, Michael L.
    [J]. TRENDS IN GENETICS, 2017, 33 (04) : 244 - 255
  • [34] A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor α promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes
    Li, HY
    Groop, L
    Nilsson, A
    Weng, JP
    Tuomi, T
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) : 2767 - 2774
  • [35] Association between LTA, TNF and AGER Polymorphisms and Late Diabetic Complications
    Lindholm, Eero
    Bakhtadze, Ekaterina
    Cilio, Corrado
    Agardh, Elisabet
    Groop, Leif
    Agardh, Carl-David
    [J]. PLOS ONE, 2008, 3 (06):
  • [36] Liu Bo, 2011, Shanghai Kou Qiang Yi Xue, V20, P169
  • [37] Impact of genetic polymorphisms of leptin and TNF-α on rosiglitazone response in Chinese patients with type 2 diabetes
    Liu, Hai-Ling
    Lin, Yang-Gen
    Wu, Jing
    Sun, Hong
    Gong, Zhi-Cheng
    Hu, Ping-Cheng
    Yin, Ji-Ye
    Zhang, Wei
    Wang, Dan
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (07) : 663 - 671
  • [38] Liu ZN, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055618, 10.1371/journal.pone.0083444]
  • [39] MANTEL N, 1959, JNCI-J NATL CANCER I, V22, P719
  • [40] Guzmán-Flores JM, 2011, DIS MARKERS, V30, P19, DOI [10.1155/2011/360312, 10.3233/DMA-2011-0759]